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As the world grapples with the HIV pandemic, the implementation of the agenda determined 
by the International Conference on Population and Development (1994) at Cairo, and the 
matter of providing health services of adequate quality in an ethical, gender-sensitive 
manner, new questions are arising about how to attend to reproductive tract infections 
(RTIs), including sexually transmitted infections (STIs), among women. The alternatives put 
forward to address this need include strategies that rely on symptoms, signs, and risk factors 
for predicting infections without laboratory diagnosis.  Such options are particularly 
appealing in settings where laboratory facilities are unavailable or the costs of building and 
sustaining them are prohibitive. 
 
What has emerged as a particularly vexing problem is the management of chlamydia and 
gonorrhea infections.  These STIs have serious health consequences, yet are largely 
asymptomatic for many women, and, among women, specific symptoms and signs do not 
appear to correlate consistently with infection.  This situation leaves us with the difficult 
challenge of distinguishing between symptomatic women with vaginal infections—such as 
bacterial vaginosis or trichomoniasis—and those who have cervical infection with chlamydia 
or gonorrhea.  Moreover, the large pool of asymptomatic chlamydia and gonorrhea cases 
makes identification of infection extremely difficult. 
 
This paper reviews the results of validation studies of syndromic algorithms, other 
nonlaboratory clinically-based tools, and risk scoring for finding women infected with 
chlamydia and gonorrhea, particularly among those attending family planning and antenatal 
clinics in developing countries.  It also examines the results of the few studies to date that 
have assessed syndromic algorithms and risk-scoring tools’ ability to manage cases of 
chlamydia and gonorrhea among women presenting to an STI clinic with genitourinary 
complaints, or among symptomatic female sex workers.  We analyze the risk factors 
explored to build such tools and review the predictive ability of the proposed and tested 
strategies.   
 ii
Meta-analysis of nonlaboratory chlamydia/gonorrhea case-finding validation studies among 
general female populations and among women attending family planning and antenatal 
clinics found positive predictive values (PPVs) of 13 percent or less.  The PPV measures the 
probability that a person identified as infected actually is infected.  (A PPV of 13 percent 
indicates that 87 percent of those people identified by a diagnostic tool as infected are not 
infected, according to laboratory diagnosis.)   These low PPVs are disappointing in terms of 
the prospects of finding cases of chlamydia and gonorrhea without causing concomitant large 
errors of overdiagnosis among women making routine visits to clinics that offer reproductive 
health services.  We conclude, as do many of the authors of the studies cited, that these tools 
are not appropriate for use in finding cases of chlamydia/gonorrhea.  On the other hand, 
studies among female sex workers, where chlamydia/gonorrhea prevalence was high (31 to 
40 percent), showed a better but not excellent ability of screening tools to identify cases 
accurately, achieving PPVs of up to 50 percent. 
 
Meta-analysis of the use of case-management tools among symptomatic women found PPVs 
ranging from 40 to 45 percent.  The tools’ ability to identify cases accurately among female 
sex workers or to manage cases among symptomatic women is better than their ability to find 
cases in general populations or among family planning and antenatal clinic clients as a result 
of the relatively higher probability of infection among sex workers and STI clinic patients. 
 
These imperfect results leave us with several challenges.  For example, at the service-
delivery point, provision of appropriate counseling is complex.  Misdiagnosing a woman—
either telling her she is infected when she is not or that she is not infected when she is—has 
ramifications.  Appropriate counseling messages and approaches that can relay the 
complexity of case-management tools’ determination must be developed. 
 
The results also raise challenges for policymakers in sorting through what course of action is 
most appropriate in a particular context.  Research and policy analysis for determining the 
best approach for addressing chlamydia/gonorrhea infection in settings with different 
prevalence rates, program capacity, and sexual behavior patterns are lacking. Finally, simple 







Women’s health advocacy and the advent of the HIV/AIDS pandemic have 
succeeded in focusing attention on the magnitude and consequences of reproductive tract 
infections (RTIs).1  With RTIs now clearly on the agenda of the reproductive health 
community, the challenge is to design and implement activities that address the problem.  
Information to guide policy choices is abundant.  For instance, RTIs are sufficiently 
prevalent to constitute a public health concern, yet their extent and severity are generally 
underestimated by professionals and the public.  Moreover, these conditions are intertwined 
with social, gender, and behavioral issues that are manifested in access to services, women’s 
health-seeking behavior, and power differentials in relationships that make it difficult for 
women to insist on condom use. 
Clinically, we know how to treat specific infections in individual patients; we know 
that infections may interact with the contraceptive services that family planning programs 
have traditionally provided; and we know that sexually transmitted infections (STIs) act as 
significant co-factors in HIV transmission. 
At the same time, we lack much information.  As we grapple with how best to expand 
and improve programs for prevention, diagnosis, and treatment, we are confronted with 
challenges, difficult decisions, and less-than-optimal choices.  For example, policy decisions 
will have to be made with an awareness of the implications of country-specific burdens of 
infection, taking into consideration the variability between and within countries in 
prevalence of different RTIs.  Some interventions can be relatively straightforward, such as 
preventing iatrogenic infections—that is, RTIs that occur as a result of medical procedures 
such as abortion and IUD insertion—through better quality of care in service-delivery 
settings.  Others are more challenging; for example, diagnosing some of the most harmful 
STIs, such as chlamydia and gonorrhea. 
STI prevention requires attention to a number of behavioral issues, including the 
timeliness of seeking medical attention and sexual behavior.  STIs are not like other 
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infections: They are highly stigmatized and reflect the unequal power dynamic of many 
relationships, including norms of masculine and feminine behavior that encourage multiple 
partners for males while limiting women’s ability to assert themselves to assure safer sex. 
Laboratory diagnosis and treatment is also complex and lies beyond the financial and 
technical capacity of the vast majority of resource-constrained health systems.  Simple 
diagnostic tests exist for some STIs,2 but not for others. Bacterial vaginosis, trichomoniasis, 
and candidiasis can be definitively diagnosed with rapid tests, but even these are not 
available at most peripheral sites.  For Neisseria gonorrhoeae (NG) and Chlamydia 
trachomatis (CT) infections, more sophisticated laboratory tests are required.   
Despite these challenges, the urgency born of recent attention to RTIs has impelled 
the international health community, some governments, and many nongovernmental service 
providers to seek to do something now to implement ideas that appear useful in addressing 
the problem. 
Among the appealing approaches are tools or strategies that seek to manage RTIs in 
low-resource settings without laboratory diagnosis.  Nonlaboratory management strategies, 
specifically syndromic algorithms and risk scoring, have been developed to assist clinicians 
in deciding in a systematic fashion—given presenting signs and symptoms and/or a client’s 
social and behavioral risk factors—whether the client may have an infection, what are the 
likely causative agents, and what is the best presumptive treatment.  These tools do not rely 
on certain diagnosis, rather on the probability that certain symptoms, signs, demographic 
characteristics, and risk behaviors are likely to be associated with infection. 
Findings in a variety of contexts have shown, however, that even when women notice 
vaginal discharge, pain, or other symptoms, they often consider such problems a woman’s 
burden to bear and do not seek appropriate health care.  “[A] large proportion of gonococcal 
and chlamydial infections in women are asymptomatic, and many infected women fail to 
seek health care.  Thus, control strategies based on active case finding are needed.” 
                                                                                                                                                                                    
1 RTIs include bacterial, viral, and protozoal infections of three basic types:  those that are sexually transmitted (such as 
chlamydia and gonorrhea); endogenous infections that result from an overgrowth of organisms normally present in the 
reproductive tract (such as candidiasis and bacterial vaginosis); and iatrogenic infections that result from medical 
procedures. 
2  For instance, trichomonas vaginalis can be diagnosed with a saline wet mount; candidiasis with 10 percent KOH 
(potassium hydroxide) prep or gram stain; and bacterial vaginosis with positive saline wet mount, amine odor when 
combined with 10 percent KOH, and vaginal pH greater than 4.5, or gram stain (Celum et al. 1994). 
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(Vuylsteke et al. 1993b:82)  Even highly symptomatic women may dismiss symptoms as 
“normal” and fail to seek care, may be unwilling to visit an STI clinic, or may not know 
whom to ask for assistance.  Yet these same women may routinely appear for family 
planning or pregnancy services.  The hope has also been expressed, therefore, that simplified 
tools might be used not only to decide how to manage the cases of women who present to 
clinicians with symptoms of RTIs but also to find cases of infection among general 
populations of sexually active women.  
The ability to identify infections with such “low-tech” tools would obviously be 
particularly important for those infections that are both difficult to diagnose in low-resource 
settings and important in terms of health consequences for women.  Candida, trichomoniasis, 
and bacterial vaginosis are, in fact, diagnosable with simple microscopy, but the health 
consequences of these infections are not thought to be severe.  Gonorrhea and chlamydia, in 
contrast, are more difficult or impossible to diagnose with the current simple technology 
available, and both can have serious health consequences.  Their presence is a 
contraindication to the provision of contraceptive methods (IUDs) that form the basis of 
many national family planning programs, and they present health risks during other common 
events such as childbirth and abortion.  Finding cases of chlamydia and gonorrhea is 
especially problematic, because a significant proportion of infected women exhibit no signs 
or symptoms. 
The attraction of management strategies such as syndromic algorithms and risk 
scoring is clear for finding chlamydia and gonorrhea cases among women seeking routine 
health services from family planning and antenatal clinics.  If tools can be developed that 
allow clinicians to find cases of chlamydia and gonorrhea among their clients, and to treat 
them appropriately, the quality of contraceptive services would improve, morbidity would 
decrease, and the transmission of STIs and HIV transmission would be slowed. As the results 
of validation trials continue to emerge, however, increasingly the predictive ability of such 
strategies to identify chlamydia and gonorrhea infections is found to be limited among the 
populations most likely to use existing reproductive health services.  Of equal concern is that 
the ability of syndromic algorithms and risk scoring to identify chlamydia and gonorrhea 
infections among the populations of women likely to be infected—such as sex workers and 
symptomatic STI clinic clients—also appears to be limited in many settings. 
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This paper reviews studies that have assessed the effectiveness of nonlaboratory 
management strategies for finding cases of gonorrhea and chlamydia infection among family 
planning, antenatal care, and general populations in developing countries, populations 
usually having relatively low-to-moderate STI prevalence.  We also look at studies in which 
nonlaboratory tools have been used to find cases of chlamydia and gonorrhea among a 
population of women for which the prevalence of STIs is relatively high (that is, female sex 
workers).  Finally, studies that assess the ability of STI management strategies to manage 
cases of infections among symptomatic women (that is, STI clinic clients and symptomatic 
female sex workers) are also reviewed.  We assess the implications of the results of the 
validation studies at the research, program, and policy levels. 
 
The Structure of the Paper 
 
Section II provides a brief overview of the importance of cervical infections and their 
prevalence derived from studies among diverse populations of women in developing 
countries. In Section III, methods for assessing the usefulness of nonlaboratory tools are 
discussed.3  We outline how associations between a factor and infection are measured, and 
how predictive ability is ascertained, and discuss what these measurements mean to 
practitioners.  This section also includes a discussion of how nonlaboratory tools are 
constructed and how they have evolved. 
Section IV reviews the results of the studies.  We summarize common correlations 
that researchers have found between chlamydia/gonorrhea infection and specific symptoms, 
signs, simple tests, and social, demographic, and behavioral characteristics in developing 
countries.  These associations represent some of the factors explored for inclusion as criteria 
in a variety of algorithms and risk-scoring tools that were created, adapted, or refined to fit 
local conditions.  This section also reviews validation studies of nonlaboratory tools 
developed to find or manage chlamydia and/or gonorrhea infection in women and concludes 
with a discussion of the results of these studies. 
                                                          
3 The term “nonlaboratory tools” will be used throughout this paper to refer to tools such as syndromic algorithms and risk 
scoring, in contrast with etiologic tests that provide a definitive diagnosis such as culture. 
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Sections V and VI consider where the accumulated knowledge leaves the field, what 
are the main gaps in our understanding, and what are the principal research, programmatic, 
and policy implications.  
 
II. Importance and Prevalence of Chlamydia and Gonorrhea Infections 
 
Women generally suffer greater health consequences than do men from sexually 
transmitted infections. Among the most serious nonviral infections are chlamydia and 
gonorrhea.  Among women, these can lead to upper reproductive tract infection, that is, 
pelvic inflammatory disease (PID) (Westrom 1980; Westrom and Mardh 1984).  Without 
treatment, PID can lead to infertility, ectopic pregnancy, chronic pelvic pain, and recurrent 
infection. In most developing country settings, increased risk of ectopic pregnancy means 
increased risk of mortality.  Among infected women, risk of pelvic inflammatory disease 
increases significantly in association with transcervical events such as abortion, IUD 
insertion, and giving birth (Ory 1978; Plummer et al. 1987; Westrom and Mardh 1989). 
STIs also affect pregnancy outcome.  Stillbirth has been associated with chlamydia, 
cytomegalovirus, and syphilis (Martin et al. 1982; Brunham et al. 1984b).  Almost every RTI 
has been associated with premature birth, intrauterine growth retardation, or both (Barnes 
1979; Hauth et al. 1995; Hillier et al. 1995).  Ophthalmia neonatorium, which, if left 
untreated can lead to blindness, is caused by gonorrhea and chlamydia, and is acquired as 
neonates pass through the infected birth canal. 
Because of their inextricable link with sexual behavior, the social consequences of 
STIs are considerable as well.  As the implications of a diagnosed STI in one partner are 
confronted, they can cause mental anguish and undermine trust in the relationship.  For 
women in abusive relationships, physical harm can result—regardless of who infected whom.  
In contexts where women’s sexuality is strictly controlled, inference or accusation of an 
extramarital sexual liaison can mean the end of a woman’s marriage, her social ostracism, 
bodily harm, and, in extreme situations, even her death. 
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Women also bear the larger burden of the social stigma associated with infertility, 
one of the possible consequences of untreated RTIs.4  Women may suffer psychologically 
when they cannot meet social expectations in their role as mothers or as a result of actual or 
de facto divorce when they are cast out of marital relationships into economically precarious 
situations.  In some cases, a woman must contend with her husband’s taking another—or an 
additional—wife or partner as a result of her infertility.   
Women are not only disproportionately affected by the health and social 
consequences of STIs but are also disproportionately vulnerable to infection because of their 
anatomy and physiology.  A woman is two times as likely as a man is to contract chlamydia 
or gonorrhea during sex with an infected partner (Donovan 1993).  Adolescent girls appear to 
have even greater vulnerability than older women because of their biologically immature 
cervices (Shafer and Sweet 1990), their hormonal changes, and their lower immunity to STIs 
(Brookman 1990).  The sexually transmitted nature of certain human papilloma virus (HPV) 
strains has been associated with several different genital tract cancers in men and women.  
Cervical cancer is the most important of these.  A woman’s risk of cervical cancer increases 
not only as her number of sexual partners increases (Muñoz et al. 1996), but also as the 
number of her partner’s sexual partners increases (Thomas et al. 1996).  
Finally, women are more vulnerable to infection because of their position in society.  
Women and girls often have limited power to determine the nature and terms of a sexual 
encounter: whether to have sex at all, whether condoms are used, whether a partner is tested 
for STIs, or whether a relationship is monogamous.  Each of these conditions will affect her 
health, yet she may be unable, or feel it is futile, to assert her needs.  “For many women, the 
perceived risk of being beaten, divorced or abandoned, or of losing a source of emotional or 
financial support, far exceeds the perceived health risk of acquiring an STD.” (Dixon-
Mueller and Wasserheit 1991:10–11) 
The World Health Organization (WHO) estimates that globally, 333 million new 
cases of curable sexually transmitted infections (syphilis, gonorrhea, chlamydia, and 
trichomoniasis) occur annually.  This figure does not include the yearly incidence of 
chancroid, HIV, human papilloma virus, hepatitis B virus, and herpes simplex virus, among 
                                                          
4 An estimated 50 to 80 percent of infertility in Africa, 15 to 40 percent of infertility in Asia, and about 35 percent of 
infertility in Latin America is caused by pelvic inflammatory disease (Wasserheit and Holmes 1992). 
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others, nor does it include endogenous RTIs such as candidiasis or bacterial vaginosis.  
Among the infections in the WHO estimate, the one thought to have the highest incidence is 
trichomoniasis, with 170 million new cases per year.  Chlamydia is second with 89 million, 
then gonorrhea with 62 million, and syphilis with 12 million new cases annually (Gerbase et 
al. 1998).  
An early comprehensive review of prevalence studies of reproductive tract infections 
conducted in developing countries (Wasserheit 1989) found few population-based studies 
available and little research on the prevalence of chlamydia and bacterial vaginosis. 
Although there was extreme variability in the nature and quality of the laboratory tests used 
in the studies reviewed, Wasserheit found RTIs to be common among women who are not 
acknowledged sex workers in almost all developing countries where data were available.  
Prevalence was higher in African populations than in those of Asia or Latin America, but 
there were no consistent prevalence patterns with respect to specific pathogens (see Table 1). 
 
Table 1   Prevalence rates of chlamydia and gonorrhea infection among women in 






Region Rates published (%) Median (%) Range (%) 
Africa 4, 6, 7, 23 10 0–40 
Asia 2, 14 1 0.3–12 
Latin America No published data 6 2–18 
Source: Wasserheit (1989). 
 
Prevalence data in this review of validation studies reinforce Wasserheit’s original 
conclusions:  STIs are common; prevalence rates appear to be higher in Africa than in other 
developing country regions; and no consistent prevalence patterns are found for specific 
pathogens. More data are available on chlamydia today than when the Wasserheit review was 





Details of selected studies investigating the prevalence of chlamydia and/or 
gonorrhea among women in Africa are shown in Table 2.5 This table is sorted by type of 
populations investigated, specifically:  asymptomatic women; general populations of 
sexually active women as represented by community-based samples and women attending 
routine clinics such as family planning or antenatal services; symptomatic women; and 
women at higher risk, such as STD clinic clients and female sex workers. 
 
Table 2  Findings from selected studies investigating prevalence of chlamydia and 
gonorrhea in Africa, by population type 
Population type Chlamydia (%) Gonorrhea (%)  




Mixed asymptomatic and 
symptomatic women 
(community-based and all or 
randomly selected clients at 
routine clinics) 
Range:  3.1–18.0; 
median: 8.0;  mean: 8.8 
(13 studies, 14 populations) 
Range: 0–10.0 
median: 3.1;  mean: 3.7 
(14 studies, 15 populations) 
Symptomatic women Range: 12.0–27.8; 
median: 20.4;  mean: 20.1 
(four studies) 
5.3, 10.9, 12.3; 
(three studies) 
STD clinic clients and female 
sex workers 
Range: 6.4–14; 
median: 13.0;  mean: 11.6 
(four studies) 
Range: 14.0–37.0; 
median: 21.2;  mean: 23.4 
(four studies) 
 
 As expected, the prevalence of chlamydia and gonorrhea is higher among 
symptomatic women, STD clinic clients, and sex workers.  Prevalence levels among general 
populations of African women are highly variable, but relatively high. Among symptomatic 
women in these studies, the prevalence of chlamydia was about one in five women, and of 
gonorrhea, about half of that. 
 
Asia and the Pacific 
 
Table 3 shows the prevalence of chlamydia and gonorrhea according to selected 
studies conducted in Asia and the Pacific. 
                                                          
5 One study by Pham-Kanter et al. (1996) is itself a review of numerous studies in South Africa. 
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Table 3  Findings from selected studies investigating the prevalence of chlamydia and 
gonorrhea in Asia and the Pacific, by population type 
Population type Chlamydia (%) Gonorrhea (%)  




Mixed asymptomatic and 
symptomatic women 
(community-based and all or 
randomly selected clients at 
routine clinics) 
Range:  0.5–24.9; 
median: 5.1;  mean: 7.2 
(12 studies, 14 populations) 
Range: 0–1.5; 
median: 0.3;  mean: 0.5 
(nine studies) 









na = Not available. 
 
Latin America and the Caribbean 
 
 Selected studies from Latin America and the Caribbean describing the prevalence of 






Table 4  Findings from selected studies investigating the prevalence of chlamydia and 
gonorrhea in Latin America and the Caribbean, by population type 
Population type Chlamydia (%) Gonorrhea (%)  
Asymptomatic women na na 
Mixed asymptomatic and 
symptomatic women 
(community-based and all or 
randomly selected clients at 
routine clinics) 
Range:  2.5–26.7; 
median: 11.5;  mean: 12.4 
(five studies, eight 
populations) 
Range: 0–2.5; 
median: 0.5;  mean: 0.9 
(three studies, six 
populations) 
Symptomatic women na na 
STD clinic clients and female 14.3, 24.9 16.4 
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sex workers (two studies) (one study) 
na = Not available. 
Conclusion 
 
Although we cannot compare these studies directly, given their variations in 
diagnostic criteria and measurement techniques, they do suggest trends.  For the populations 
studied, with the exception of sex workers and women attending STD clinics, chlamydia has 
a higher prevalence than does gonorrhea.  The prevalence of gonorrhea appears to hover 
below 3 percent in Asia and in Latin America and the Caribbean, and, again, excepting the 
rates for STD clinic clients and female sex workers, it is generally below 10 percent in 
Africa.  In contrast, the prevalence of chlamydia seems to vary widely across and within 
regions—from below 5 percent to around 25 percent in all regions. 
 
III. Algorithms and Other Nonlaboratory, Clinically-based Tools:  What Are They?  
How Are They Developed? How Do We Judge Their Efficacy? 
 
To understand how management strategies such as syndromic algorithms and risk 
scoring work, how we can measure their usefulness, and what they can and cannot do, this 






Treatment for disease is indicated when the best available test to detect the 
condition—called the standard diagnostic test—is positive.  Standard diagnostic tests identify 
the presence of the infectious pathogen, primarily through laboratory-based processes, 
thereby determining as nearly as possible whether a person is infected or not. Although 
standard diagnostic tests are frequently referred to as the “gold” standard, this is not a 
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completely accurate descriptor, because even the best diagnostic tools currently available are 
imperfect. 
In terms of reproductive tract infections, the most prevalent are those that are more 
easily diagnosed and those with less severe sequelae, such as trichomoniasis, candidiasis, and 
bacterial vaginosis. As yet, no simple, inexpensive means exist for diagnosing cervical 
gonorrheal and chlamydial infections.  The test most commonly used for gonorrhea diagnosis 
is culture (86–96 percent sensitive; see Wentworth et al. 1991), which requires a culture 
medium, an incubator, an enriched CO2 environment, careful handling in transport to a lab if 
an incubator is not available locally, and a trained technician.  Chlamydia culture, also 
complex and reported to be 89 percent sensitive (Wentworth et al. 1991), is not used as the 
standard diagnosis in most studies.  Other tests are more commonly used for chlamydia 
diagnosis and are less sensitive (direct fluorescent antibody [DFA] and enzyme immunoassay 
[EIA]).  More recently, polymerase chain reaction (PCR) and ligase chain reaction (LCR) 
have emerged as the standard tests for chlamydia, with sensitivity and specificity better than 
those from culture (Buimer et al. 1996; Gray and Wawer 1996; Puolakkainen et al. 1998; 




Screening mechanisms, whether they employ nondefinitive diagnostic laboratory 
tests, or variables identified through physical exams or questionnaires, either singly or 
grouped into complex algorithms, attempt to sort a subgroup of persons who probably have a 
disease from those who probably do not.  Individuals screened as “positive” are not 
diagnosed with a disease by the screen, rather they are referred for definitive laboratory 
diagnosis and given appropriate treatment.  Such selective screening seeks to minimize the 
number of “gold-standard” diagnostic tests performed while maximizing the identification of 
infections.  “Universal screening” is the term for the nonselective testing of everyone in the 
population with the definitive diagnostic test. 
Selective screening for chlamydia might involve choosing and testing a subgroup of 
clients that has a higher suspected prevalence of infection (for example, young women with 
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multiple partners) than that among all women attending a family planning clinic. This 
strategy avoids testing clients who are thought unlikely to be infected, thereby theoretically 
increasing the prevalence rate of infection among the identified subgroup and increasing the 
predictive value of the screening test (see discussion below on the effects of prevalence on 
positive predictive value).   
As noted above, in the cases of chlamydia and gonorrhea, many women are 
asymptomatic, and because existing standard diagnostic tests are expensive and laboratory-
dependent, selective screening is an enticing option.  By looking at various combinations of 
symptoms, signs, risk factors, and the results of simple tests, researchers in developed 
countries have tried to identify criteria that maximize the number of infected individuals and 
minimize the number of uninfected individuals identified as “possibly infected” by the 
screening test. 
In the United States, selective screening for chlamydia based on clinical signs and 
risk factors, followed by standard diagnostic testing of individuals with a positive screen and 
treatment of individuals with a positive diagnosis, has been associated with a decrease in the 
prevalence of chlamydia in family planning clinics in Wisconsin (Addiss et al. 1993) and in 
four other states (Alaska, Idaho, Oregon, and Washington) (Britton et al. 1992).  
 
Nonlaboratory Tools for Case Management and Case Finding 
 
The use of standard laboratory tests for chlamydia and gonorrhea is logistically and 
economically infeasible in many developing countries, particularly in rural settings.  
Therefore, several types of alternatives to laboratory diagnosis of these infections are 
currently being pursued by the international health-care community.  These include the 
development of inexpensive field-based diagnostics, periodic presumptive treatment of high-
risk populations, and tracing the female partners of symptomatic men.  Other efforts include 
the development of management strategies such as syndromic algorithms and risk-scoring 
tools.  These management strategies are based on the premise that certain variables (signs, 
symptoms, behaviors) indicate reliably the existence of a specific infection that can be 
treated effectively with available medication.   
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The syndromic approach to the management of reproductive tract infections classifies 
syndromes, that is, constellations of symptoms and signs associated with a number of 
pathogens and recommends drugs that treat the majority of organisms responsible for that 
syndrome.  A clinical algorithm—a step-by-step logical flowchart—is intended for use when 
a patient with a syndrome presents for treatment.  It guides the clinician’s decisionmaking in 
identifying the probable infection and recommending appropriate treatment. 
Such an approach has the advantage of not requiring laboratory facilities.  In addition, 
patients are treated immediately, so they do not have to return for diagnosis, thereby reducing 
potential loss to follow-up and complications or further transmission during the interim 
between initial presentation and definitive diagnosis.  Other advantages relate to standardized 
diagnosis, treatment, referral, data collection, and supervision of health-care workers 
(Vuylsteke and Meheus 1996). 
In clinical use, flowcharts for genital ulcers among men and women have been shown 
to perform adequately as tools to manage cases of syphilis and chancroid infection 
(Vuylsteke and Meheus 1996; Ryan and Holmes 1995; Adler 1996). Unfortunately, vaginal 
discharge is more complicated.  It is difficult to use algorithms to distinguish between 
vaginal infections (often caused by endogenous RTIs such as bacterial vaginosis and 
candidiasis) and cervical infections (primarily sexually transmitted and caused by chlamydia 
and/or gonorrhea).  These two types of infection require different counseling, follow-up, and 
medications.  In an effort to address this problem, interview questions designed for 
predicting risk—that is, questions based on demographic and behavioral variables thought to 
be associated with chlamydia and gonorrhea—have been used as a way of attempting to 
distinguish symptomatic women with and without cervical infection.   
At the same time, researchers have documented substantial levels of RTIs among 
women who are not among high-risk populations.  Furthermore, women’s health advocates 
are successfully calling attention to the fact that although the understanding had always been 
that family planning methods should not be provided without knowledge of a woman’s 
RTI/STI status, in practice this precaution is rarely taken.   
Whereas case-management guidelines direct treatment for clients who come to a 
clinic with complaints, case finding actively seeks to identify cases of infection among clinic 
clients and general populations regardless of their symptom status.  In the majority of 
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developing country settings where standard diagnostic tests are unavailable, case 
management through syndromic algorithms and risk scoring is intended as a substitute for 
definitive laboratory diagnosis of symptomatic women. Case finding in these settings is 
similar to screening in that it involves searching for cases of infection among asymptomatic 
women, as well as among women with symptoms who are not seeking care for RTIs, or 
women with unrecognized symptoms and/or signs.  Such case finding in low-resource 
settings differs from typical screening in that referral for definitive laboratory diagnosis 
would rarely be possible.  Instead, the screening results are used to guide presumptive 
treatment. 
 
Measures to Determine the Usefulness of Screening Tests and Case-management/finding 
Tools 
 
Specific criteria exist to evaluate the usefulness of screening tools.  These criteria, 
which can also be used to assess other case-management/finding tools, are simplicity, 
acceptability, cost, accuracy, consistency, and efficiency (Galen 1979; Mausner and Kramer 
1985).  Simplicity implies that the tool is easy to administer.  Acceptability and affordability 
of the tool are associated with higher likelihood of use.  The test must provide a true measure 
of the conditions that it is supposed to identify (accuracy) and produce the same results when 
it is repeated (consistency).  Most important, the test must be efficient—that is, it must 
identify correctly most cases of infection (sensitivity), and most individuals without infection 
(specificity),6 without falsely identifying many individuals as having the condition when they 
do not (false-positive rate). 
Positive predictive value (PPV), that is, 100 percent minus the false-positive rate, 
denotes the proportion of people who are identified as having the disease (as determined by 
the screening test or management tool) who, in fact, are infected (as determined by the 
standard laboratory diagnostic tests). Similarly, the negative predictive value (NPV) is the 
probability that a person identified by means of a tool (algorithm, risk score, or other 
                                                          
6 An ideal test or algorithm would have 100 percent sensitivity and 100 percent specificity.  In practice, neither measure  
reaches 100 percent, and a decision to choose a cutoff point with higher sensitivity is accompanied by lower specificity and 
vice versa.  Sensitivity plus specificity must be greater than 100 percent (that is, test efficiency greater than 50 percent) if a 
test is to give better results than would be obtained by chance (Galen 1979). 
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method) as negative does not, in fact, have the disease, according to laboratory diagnosis. 
The FP and PPV rates are affected by the prevalence of the disease in the population and the 
algorithm’s sensitivity and specificity. 
The efficiency of a test indicates the proportion of infected and noninfected people 
who are correctly identified—that is, it reflects both sensitivity and specificity (and, 
therefore, FP/PPV). Efficiency thus measures the ability of a test to correctly label infected 
people as positive and noninfected people as negative; it is the sum of true positives and true 
negatives divided by the total number of people in the sample.  Efficiency is also affected by 
the prevalence of disease in the population, but in the opposite direction of the way PPV is 
affected.  With a low-prevalence condition, even a poor test can have high efficiency so long 
as it classifies the great majority of people as uninfected. 
The measures commonly used to discuss the performance of algorithms, risk scores, 
and screening tests are shown in Table 5. As described in this table, nonlaboratory case-
management/finding tools use the presence of signs, symptoms, and risk factors to guide 
presumptive treatment.  To construct such tools, variables must be found that are strongly 
predictive of a disease by determining whether an association exists between a variable—for 
example, a symptom (what a client reports), sign (clinician’s observation), test, exposure, or 
behavior—and the disease.  The hope is to find indicators that allow us to make relevant 
clinical predictions. 
Table 5  Measures used to discuss performance of algorithms and risk scores 
 
Tool performance 
Person actually has 
condition 
Person does not actually have 
condition 
Total 
Identifies person as 
having the condition 
 
True Positives (TP) False Positives (FP) TP+FP 
Identifies person as not 




True Negatives (TN) TN+FN 
Total TP+FN TN+FP n 
Prevalence = (TP+FN)÷n. 
Odds ratio = (TPxTN)÷(FP x FN). 
Sensitivity  =  TP÷(TP+FN). 
Specificity = TN÷(TN+FP). 
False-positive rate = FP÷(TP+FP). 
Positive predictive value = TP÷(TP+FP), or 100 - FP rate. 
Negative predictive value = TN÷(TN+FN).  
Test efficiency = (TP+TN)÷n. 
 n = sample. 
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The odds ratio (OR) describes the odds of a person’s having a disease with the factor 
present compared to the odds of having a disease with the factor absent (Mausner and 
Kramer 1985).  The odds ratio indicates the strength of the association between a factor and a 
disease, whereas statistical significance indicates the probability of the association.  An OR 
of 2.9, for instance, indicates that people exhibiting the designated characteristic have a risk 
of disease almost three times greater than do those who do not exhibit this factor.  An OR of 
1.75 indicates that the risk of disease is 1.75 times (or 75 percent) higher among those 
exposed to a given variable than among those who were not exposed.   
The OR and its significance indicate the strength of an association and the likelihood 
that the association is not due to chance, and, therefore, suggest which variables might be 
included in screening or case-management/finding tools.  Yet, strong statistical associations 
(generally odds ratios, and sometimes regression coefficients) found between certain signs, 
symptoms, or behavioral characteristics and disease status do not provide all the necessary 
information. 
Analyses from one of the papers reviewed here illustrate this point:  Vuylsteke et al. 
(1993b) conducted a study in an antenatal clinic in Zaire where the prevalence of chlamydia 
and gonorrhea was moderate (6.5 percent) (see Table 6).  Women having a positive cervical 
swab result (10 or more polymorphonuclear leukocytes [PMNs] per high-powered field) had 
a 2.2 times greater risk (that is, OR = 2.2) of chlamydia/gonorrhea infection than did women 
with a negative swab.  This finding was highly statistically significant (p<0.001), because 
most women did not have chlamydia or gonorrhea, and most women without infection in this 
Table 6  Association of cervical swab results with chlamydial or gonorrheal infection 
among 1,160 women tested, Zaire 
 
 


























Total TP+FN = 75 FP+TN = 1,085 n = 1,160 
PMNS = polymorphonuclear leukocytes. 
Prevalence = (75)÷1,160 = 6.5 percent. 
Odds ratio = (31x 824)÷(261x44) = 2.22; p<0.001, highly statistically significant. 
Sensitivity  =  31÷(75) = 41.3 percent. 
Specificity = 824÷(1,085) = 75.9 percent. 
False-positive rate = 261÷(292) = 89.4 percent. 
Positive predictive value = 31÷(292) = 10.6 percent. 
Negative predictive value = 824÷(868) = 94.9 percent. 
Test efficiency = (31+824)÷1,160 = 73.7 percent. 
Source: Vuylsteke et al. (1993b). 
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large sample were correctly identified (824 of 1,085; specificity = 76 percent).  Still, fewer 
than half of those having chlamydia/gonorrhea would have been correctly identified (31 of 
75) if the swab test for PMNs were used as a screening test, and 44 of the 75 women 
requiring treatment would not have received it were this screening criterion used.  Also, in 
comparison with the 31 women correctly identified as being infected, more than eight times 
as many women (261) who were not infected would have been falsely identified as having 
chlamydia/gonorrhea and would have received inappropriate treatment.  The researchers thus 
concluded that this variable was not sensitive and specific enough to use as a proxy for the 
definitive detection of infection.  
Such results using single factors are not uncommon. Therefore, several of the most 
indicative variables are frequently combined to build screening or case-management/finding 
tools.  Tools that include multiple variables should also be evaluated based on sensitivity, 
specificity, PPV, false-positive rate, NPV, and test efficiency.  
In the same study, the authors found similar results despite using multiple variables in 
a scoring system (see Table 7).  The association (odds ratio) between women’s having a 
positive score and having chlamydia/gonorrhea infection was highly statistically significant 
(OR = 7.12, p<0.001), because most women did not have chlamydia or gonorrhea, and most 
women without infection were correctly identified (797 of 1,085, specificity = 73.5 percent).  
More than half of those having chlamydia/gonorrhea would have been correctly identified 
(54 of 75) were the score used as a screening test; yet, 21 of the 75 women requiring 
treatment would not have received it were this screening criterion used.  Also, in comparison 
with the 54 women who were correctly identified as being infected, more than five times as 
Table 7  Association of positive and negative scores from multiple variables with chlamydial 





Has chlamydia or 
gonorrhea 


















Total TP+FN = 75 FP+TN = 1,085 n = 1,160 
Prevalence = (75)÷1,160 = 6.5 percent. 
Odds ratio = (54x797) ÷ (288x21) = 7.12; p<0.001, highly statistically significant. 
Sensitivity  = 54÷(75) = 72.0 percent. 
Specificity = 797÷(1,085) = 73.5 percent. 
False-positive rate = 288÷(1,342) = 84.2 percent. 
Positive predictive value = 54÷(342) = 15.8 percent. 
Negative predictive value = 797÷(828) = 96.3 percent. 
Test efficiency = (54 + 797)÷1,160 = 73.4 percent. 
Source: Vuylsteke et al. (1993b). 
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many women (288) who were not infected would have been falsely identified as having 
chlamydia/gonorrhea and would have received inappropriate treatment. 
 
Whereas all these measures are informative, the most important criteria for evaluating 
the usefulness of a screening tool or case management/finding tool are:  (1) the proportion of 
women with the disease who were correctly identified (that is, the sensitivity of the tool), to 
ensure that most women requiring treatment will get it; and (2) the number and proportion of 
women identified as having the condition when they do not (that is, false positives and false-
positive rates), to minimize the number of women who receive inappropriate care. 
 Although both criteria are used to evaluate screening tools in general, case-
management strategies, which are applied only to symptomatic patients, clearly cannot 
determine the proportion of asymptomatic women missed (see Table 5).  Management 
strategies are applied only to symptomatic patients and therefore can be evaluated only on 
the basis of the proportion of symptomatic women correctly or inappropriately treated (that 
is, the number and rate of false positives, or conversely, the positive predictive value).7  Non-
laboratory tools used to find cases—that is, tools applied to symptomatic and asymptomatic 






In two sections below, we review studies of (1) correlations of symptoms, signs, and 
risk factors with diagnosed infection and (2) validation trials of nonlaboratory tools for 
managing and/or finding chlamydia and gonorrhea in developing countries.  Peer-reviewed, 
published, validation studies of chlamydia/gonorrhea-management strategies were identified 
through computer databases, specifically PopLine and MedLine from 1990 through 1997. 8  
                                                          
7 Sensitivity and specificity of the test cannot be estimated because asymptomatic women are not tested diagnostically, so 
we do not know how many of them are categorized accurately (true negatives) and inaccurately (false negatives). 
8 As this paper was being finished, a special supplement to the journal Sexually Transmitted Infections (Vol. 74, Supplement 
1, 1998) was published that contains several studies on chlamydia and gonorrhea case management and finding. It is an 
excellent compilation that readers of this paper will find of interest. Results of the studies published in the supplement are 
similar to those reviewed here. 
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Unpublished literature and presentations at conferences during those years were also 
compiled. 
Fifteen studies were included on the basis of their methodological soundness and 
their use of standard diagnostic tests to identify infection.  Chlamydia was diagnosed in these 
studies with culture (Braddick et al. 1990); enzyme immunoassay (Kapiga et al. 1996; 
Vuylsteke et al. 1993b; Kaufman et al. 1996; Behets et al. 1995; Thomas et al. 1994; and 
Bourgeois et al. 1996); antigen detection enzyme immunoassay and confirmatory blocking 
antibody assay (Mayaud et al. 1995;  Thongkrajai 1996; Meda et al. 1997); enzyme 
immunoassay confirmed by direct fluorescent assay (Ronsmans et al. 1996); enzyme 
immunoassay and ligase chain reaction (Coetzee and Mathews 1998); enzyme immunoassay 
and various polymerase chain reaction assays (Germain et al. 1997); and direct 
immunofluorescent assay (Acosta-Cazares et al. 1996).  Gonorrhea  was diagnosed in most 
of these studies with culture, except in one (Germain et al. 1997), which used culture or PCR 
assays. 
Most studies tested the ability of algorithms, risk scoring, and other tools to find cases 
of chlamydia and/or gonorrhea among routine clinic and general populations of women.  
Two were conducted among community-based populations (Ronsmans et al. 1996; Kaufman 
et al. 1996), six among antenatal clinic clients (Braddick et al. 1990; Mayaud et al. 1995; 
Vuylsteke et al. 1993b; Bourgeois et al. 1996; Meda et al. 1997; and Thomas et al. 1994), 
two among family planning clinic clients (Costello Daly et al. 1994; Kapiga et al. 1996), one 
among combined family planning and antenatal clinic clients (Thongkrajai 1996), and one 
among patients in a rural hospital (Acosta-Cazares et al. 1996).  Some of these studies tested 
tools recommended by WHO, or national guidelines; others sought to find variables that 
might be used to construct algorithms or other clinically-based nonlaboratory tools 
appropriate for the local setting and disease patterns; and still others did both.  In all of these 
studies, both symptomatic and asymptomatic women were included—by selecting a 
community sample, by selecting women who attended a clinic within a certain time period, 
or by selecting women randomly from among all clinic clients.  Two studies analyzed 
different tools’ abilities to find cases of chlamydia/gonorrhea among populations engaging in 
high-risk behaviors, that is, female sex workers (Germain et al. 1997; and Vuylsteke et al. 
1993b). 
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Three studies applied different algorithms as case-management tools (Behets et al. 
1995; Coetzee and Mathews 1998; Germain et al. 1997).  One of these (Behets et al. 1995) 
applied the algorithms in a field setting among STD clinic clients: Women with any 
urogenital complaint who presented to the STD clinic were evaluated and treated using 
algorithms.  Another (Coetzee and Mathews 1998) simulated application of alternative-age 
cutoff points for the standard syndrome-based algorithm used in the province among 
symptomatic women attending an STD clinic.  The final study (Germain et al. 1997) 
simulated application of a screening algorithm among a symptomatic subpopulation of the 
same female sex workers in Bénin. 
Eight of the 12 studies among women attending routine clinics or general populations 
examine the ability of a management strategy to find either chlamydia or gonorrhea 
infection.  Of the other four, three (Ronsmans et al. 1996; Acosta-Cazares et al. 1996; and 
Thongkrajai 1996) look only at chlamydia, and the other (Costello Daly et al. 1994) studies 
only gonorrhea.  Combined chlamydia/gonorrhea prevalence rates in these routine-clinic 
study populations were all lower than 16 percent.  The studies of sex workers found 
combined chlamydia/gonorrhea prevalences of 31 percent (Vuylsteke et al. 1993b) and 40 
percent (Germain et al. 1997).  The studies that tested various tools’ abilities to manage cases 
among symptomatic women found a chlamydia/gonorrhea prevalence of 34 percent (Behets 
et al. 1995), 27 percent (Coetzee and Mathews 1998), and 47 percent (Germain et al. 1997). 
Finally, to supplement these data, we collected articles and abstracts, published 
predominantly from 1990 onward, that looked at chlamydia/gonorrhea correlates.  Of these, 
two provided sufficient data to include them in the analysis of correlations between risk 
factors and chlamydia/gonorrhea infection.  They did not evaluate case-management/finding 
tools, however, and thus are referred to only in the correlations discussion below.  One study 
was conducted among routine clinic clients and included a small proportion (fewer than 10 
percent) of sex workers9 (Herrmann et al. 1996).  Polymerase chain reaction and direct 
fluorescent antibody tests were used to diagnose chlamydia infection; gonorrhea infection 
was not examined.  The other study was conducted among a general population of rural 
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women, and used PCR and culture to diagnose chlamydia and gonorrhea respectively 
(Thongkrajai and Pengsaa 1997).   
For both the correlations section and the section reviewing assessments of 
nonlaboratory tools for case finding and case management, we examine the sensitivity, 
specificity, positive predictive value, false-positive rate, and test efficiency.  These measures 
are presented by selected individual variables and tools for each study included in the review.   
                                                                                                                                                                                                                                                                                                                                                                        9 The study looked at routine clinic attenders (gynecological, family planning, and prenatal clinics) and sex workers, but the 
latter comprised less than 10 percent of the entire sample (926), so we have included the results in the discussion of 
general/routine clinic populations.  The variables within this study were symptoms of vaginal discharge, abdominal pain, 
and itching;  and signs of vaginal discharge, mucopus on cervix, edema of cervix, friability, and ectropion.  Social, 
demographic, and behavioral variables were analyzed with regard to only the 863 women attending the routine clinics. 
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We also conducted meta-analyses for each of these variables and types of tools.10  The 
meta-analysis was conducted by pooling the samples (individuals) from all the studies within 
each specified category.  For instance, results of all algorithms of a defined type, such as risk 
scoring, that were used for case finding in routine clinic and general populations were 
combined.  If a study tested more than one algorithm or risk-scoring tool, or tested a variable 
or tool separately for chlamydia and gonorrhea, only the one with the best test efficiency was 
used so as to include each study only once and to give the greatest chance of producing the 
highest screening usefulness. 
Because of the way this meta-analysis was conducted, studies with larger sample 
sizes automatically have a greater weight than do those with smaller numbers of participants.  
Studies were not reweighted in any other manner (for example, by the methodological 
strength or weakness of a study), because diagnostic tests and methods used in the studies 
appeared sound.  The meta-analysis process generated sample sizes from about 300 to 9,900. 
 
Correlations of Symptoms, Signs, and Risk Factors with Infection 
 
This section reviews the factors that were found to be useful predictors and poor 
predictors of chlamydia and gonorrhea infection.  The analyses presented focus on bivariate 
associations—that is, relationships between one variable and the disease. Bivariate 
associations are immediately useful in developing clinical guidelines:  Underlying 
associations are not at issue, and, if they work, the observer can predict reliably one 
condition (infection) from one observation (the associated variable).  In contrast, multivariate 
analyses consider multiple factors to determine whether an independent association exists 
between a variable and a disease. Although multivariate analyses are important for identifing 
the “real” relationships between variables and disease, they are less useful to the clinician, 
who is mostly interested in predictors of disease, not in whether an actual cause-and-effect 
relationship exists.  For instance, in a specific population, a strong bivariate association 
between pill use and chlamydia/gonorrhea may exist that, when age is considered, disappears 
                                                          
10 Meta-analysis is helpful for obtaining a general summary impression. Looking at the results from the individual studies is 
important as well, however, for meta-analysis can obscure a range of varying conclusions and can be skewed by the results 
of one particularly large study; regional variation is also lost. 
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upon multivariate analysis.  The fact still stands, however, that women in this population 
who use oral contraceptives are more likely to be (have greater odds of  being) infected with 
chlamydia/gonorrhea, regardless of the “real” reason.  Therefore, the use of oral 
contraceptives could be a valuable indicator in this population, independent of or in 
conjunction with other variables. 
The studies investigated symptoms, signs, simple tests, and demographic and 
behavioral characteristics for their association with infection.  Looking at the results of these 
analyses helps to illuminate why chlamydia and gonorrhea are such difficult infections to 
detect. 
Appendix Tables A1 through A16 present a detailed analysis of common variables 
investigated for their relation to chlamydia and gonorrhea infection.  For each variable, we 
also conducted a meta-analysis according to the prevalence of the condition, which is 
affected by the type of study and study population.  We examined:  
 
(1) studies among general and routine clinic populations with moderate prevalence of 
chlamydia and gonorrhea, including both symptomatic and asymptomatic women, 
designed to explore the usefulness of case-finding tools or to determine the variables 
associated with infection;   
(2) studies including both symptomatic and asymptomatic women that tested the ability of 
tools to find cases among female sex workers having a relatively high prevalence of 
chlamydia/gonorrhea infection; and  
(3) validation studies of case-management tools used among symptomatic women. 
 
Data from the studies among symptomatic and asymptomatic women attending 
routine clinics or in general populations, are presented in Appendix Tables A1 through A16 
and in Table 8 below in summary meta-analyses.  Both the individual studies and the meta-
analyses show that in these groups, variables generally do not correlate consistently with 
infection, demonstrating poor sensitivity and high false-positive rates.   
Among symptoms examined in meta-analysis, for instance, only 28 percent of women 
with chlamydia/gonorrhea infection noted the symptom of vaginal discharge.  Appendix 
Table A1 shows sensitivities ranging from 4 to 77 percent, with the majority of studies 
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finding that self-reported vaginal discharge identified 30 percent or fewer of those needing 
treatment.  The meta-analysis data also show that 92 percent of those with the symptom of 
vaginal discharge (with a range of 84 to 96 percent) did not have chlamydia/gonorrhea and, 
therefore, did not require treatment for these infections.  
In these same populations, the only clinician-identified sign that, in meta-analysis, 
was found among more than 50 percent of women with chlamydia/gonorrhea infection was 
vaginal discharge.  Appendix Table A4 shows that the sign of vaginal discharge was present 
in 3 to 89 percent of those women infected.  At the same time, between 79 and 99.6 percent 
of women who had the sign of vaginal discharge did not have chlamydia or gonorrhea.  Thus, 
if clinicians had used the sign of vaginal discharge to determine whether treatment for 
chlamydia/gonorrhea were necessary, they would have incorrectly identified ten times as 
many women for inappropriate than for appropriate treatment. 
Simple tests—such as leukocyte esterase dipstick or microscopic analysis of 
polymorphonuclear leukocytes—also did not show good predictive ability (see Table 8 and 
Appendix Tables A8 and A9) in this population.   
Among demographic and behavioral variables examined (Appendix Tables A10 
through A16), only young age and not using condoms were associated with 50 percent or 
more of infections in meta-analyses.  The PPV (meta-analysis) of these variables, however, 
was low: 6 percent for young age, and 4 percent for not using condoms.  Thus, between 79 
and 99 percent of women of young age, and between 81 and 97 percent of women who did 
not use condoms did not have chlamydia/gonorrhea. 
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Table 8  Meta-analysis of symptoms, signs, and risk factors among mixed symptomatic and 
















































































































































































































































LED = Leukocyte esterase dipstick. PMNS = Polymorphonuclear leukocytes. 
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Data from research among populations including both symptomatic and 
asymptomatic female sex workers demonstrate that the predictive ability of specific variables 
for chlamydia/gonorrhea infection improves when the prevalence of infection increases. 
The false-positive rate generally declines (and the PPV generally improves) in groups 
showing higher prevalence, because more people actually have the infection. Nevertheless, 
sensitivity and the false-positive rate are equally important when the condition is more com-
mon (between 25 percent and 75 percent), as is overall test efficiency. Data from the 
Vuylsteke et al.(1993b) study of female sex workers in Zaire among whom the prevalence of 
chlamydia and gonorrhea was high (31 percent) illustrate this point.  The PPV of cervical 
ectopy is higher among the female sex workers (42 percent) than among pregnant women (11 
percent).  However, only 12 percent of the female sex workers with chlamydia/gonorrhea had 
cervical ectopy (see Table 9).  Indeed, there were more uninfected women (60) who had cer-
vical ectopy than there were women who had chlamydia/gonorrhea and cervical ectopy (44).  
 
 
Data from the two studies among symptomatic and asymptomatic populations of 
female sex workers (chlamydia/gonorrhea prevalence of 31 and 40 percent) are shown in 
Appendix Tables A1 through A16 and in the summary meta-analysis below in Table 10.  Of 
the symptoms and signs examined, only one variable had sensitivity greater than 50 percent:  
For the sign of vaginal discharge, Vuylsteke et al. (1993b) found 63 percent sensitivity and 
Table 9  Association of cervical ectopy with chlamydial or gonorrheal infection among 





Has chlamydia or 
gonorrhea 






Has cervical ectopy  True Positives 
 44 
False Positives 
    60 
TP+FP 
104 








Total TP+FN = 379 FP+TN = 843 n = 1,222 
Prevalence = (379)÷1,222 = 31.0 percent. 
Odds ratio = (44x783)÷(60x335) = 1.71; p < 0.01. 
Sensitivity  =  44÷(379) = 11.6 percent. 
Specificity = 783÷(843) = 92.9 percent. 
False-positive rate = 60÷(104) = 57.7 percent. 
Positive predictive value = 44÷(104) = 42.3 percent. 
Test efficiency = (44+783)÷1,222 = 67.7 percent. 
Source: Vuylsteke et al. (1993b). 
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Germain et al. (1997) found 58 percent sensitivity (Appendix Table A4).  The PPV for the 
sign of vaginal discharge among these women was 36 and 55 percent—that is, of the women 
with the sign of vaginal discharge, 64 and 45 percent (Vuylsteke and Germain, respectively) 
did not have chlamydia/gonorrhea infection. 
 
 
Demographic and behavioral risk characteristics (Appendix Tables A10 through A16) 
had better sensitivity (ranging from 64 to 88 percent), but generally low specificity (12 to 58 
percent).  This situation leads to high false-positive rates (59 to 69 percent) in groups for 
which 50 percent or more of the women are not infected. 
Overall, the symptoms, signs, and risk factors investigated have higher PPVs among 
female sex workers than among routine clinic attendees and general populations, ranging 
from 31 to 73 percent.  Sensitivity of these variables among female sex workers also appears 
to be slightly higher, with the exception of cervical signs (mucopus, cervical friability, and 
cervical ectopy). 
Table 10  Meta-analysis of symptoms, signs, and risk factors among mixed symptomatic and 











































































































































a Because multiple studies are lacking, this specification represents single-study results rather than meta-
analysis. 
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Data from the validation studies of syndromic case-management tools give an 
indication of the degree to which different variables correlate with chlamydia and gonorrhea 
infection among symptomatic women.  An additional caveat is that symptomatic women in 
some of these studies were seeking services at an STD clinic and may have already suspected 
that they might be infected.  The variables for which data were available to calculate 




Even in this population, where prevalence is high and the women are seeking care for a 
suspected STI, the variables investigated perform only poorly to moderately well (PPV from 
34 to 64 percent). 
 
Results of Assessments of Nonlaboratory Tools Used for Case Finding and Case 
Management of Chlamydia and Gonorrhea 
 
The associations found in bi- or multivariate analyses have been used to construct and 
adapt algorithms and risk-assessment tools.  No single variable consistently predicts 
chlamydia and gonorrhea infection, as is demonstrated in the data above, but combinations of 
variables identified via laboratory tests, physical exams, or questionnaires have been thought 
potentially to perform better.  As noted above, the advantage of such an approach is that it 
does not require laboratory diagnosis or facilities and eliminates the need to delay treatment.  
If such a system proves to have high sensitivity, low false-positive rates, and high test 
efficiency, a syndromic approach could help standardize diagnosis, treatment, and referral; 
Table 11  Meta-analysis of signs and risk factors among symptomatic women seeking services 
at STD clinics  












































a Because multiple studies are lacking, this specification represents single-study results rather than meta-analysis.
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simplify RTI data collection, analysis, and reporting from different health facilities; and 
facilitate supervision (Vuylsteke and Meheus 1996). 
In this section, we review studies that have assessed the performance of various 
nonlaboratory tools, categorized here as follows: 
 
(1)  Types of tools evaluated:   
• Simple tools  Tools based only on symptoms and/or signs in settings where a 
speculum exam is not possible.  These include, individually or in combination, 
symptoms and signs such as dysuria or vaginal discharge. 
• Simple tools using a speculum exam  Tools that include a speculum exam or those 
based solely on signs determined during a speculum exam, such as endocervical 
mucopus or cervical friability.  Some also include simple microscopy tests. 
• Tools with risk factors  Tools that include background or behavioral factors such as 
marital status, age, having more than one sex partner, or those including risk factors 
in combination with symptoms, signs, and/or simple tests. 
• Risk scoring  Risk scoring assigns values to the presence of particular variables 
(symptoms, signs, and/or risk factors).  If the total reaches a certain cutoff point, the 
woman is treated for infection.  This approach differs from the other tools in that it 
considers multiple variables simultaneously and weights some variables as more 
important than others by assigning them a higher value.  This is the most complex 
way to integrate information in a management tool. 
 
(2)  Uses to which tools are put, categorized, where appropriate, by the types of populations 
in which the tools are evaluated:  
• Case finding among: 
♦ mixed populations of symptomatic and asymptomatic women among 
general and routine clinic populations 
♦ mixed populations of symptomatic and asymptomatic women among 
populations engaged in high-risk behavior, that is, female sex workers 
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• Case management among symptomatic women attending an STI clinic or among 
symptomatic female sex workers 
Simple Tools Without Speculum Exams 
 
Case finding: routine clinic and general populations (moderate prevalence) 
Five simple tools were tested in four of the studies among routine clinic/general 
populations (see Appendix Table A17).  Predictive value, in meta-analysis, was 11 percent 
(ranging from 9 to 16 percent). In this same analysis, the tools were able to identify 38 
percent of women with chlamydia/gonorrhea (sensitivities ranged from 24 to 72 percent, with 
only one of the five tools having a sensitivity greater than 60 percent).  The algorithm with 
the highest sensitivity used any symptom related to the genital tract and successfully 
identified 72 percent of individuals with chlamydia/gonorrhea, but would unnecessarily treat 
91 percent of those identified with the algorithm (PPV equals 9 percent), resulting in an 
overall test efficiency of 38 percent (Mayaud et al. 1995). 
 
Case finding:  female sex worker populations (high prevalence) 
In addition to antenatal clinic clients, the study in Zaire (Vuylsteke et al. 1993b) also 
looked at a population of female sex workers (see Appendix Table A17). For this population, 
the simple algorithm for vaginal discharge and abdominal pain gave a PPV of 34 percent, 
and sensitivity and specificity of 55 and 52 percent, respectively.  The tool was, therefore, 
better able to find cases among sex workers than among antenatal clinic clients (PPV among 
antenatal clinic clients was 12 percent and sensitivity was 48 percent).  However, two-thirds 
of female sex workers identified as infected by the algorithm would, in fact, not be, and 




Tools Using Speculum Exams 
 
Case finding: routine clinic and general populations (moderate prevalence) 
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Seven of the studies looked at ten tools for case finding among women in this 
population (see Appendix Table A18).  The test efficiency of the tools, in meta-analysis, was 
83 percent, but the ability of the tools to identify infected women is poor.  Sensitivity of the 
tools was 25 percent, with most tools identifying fewer than 50 percent of chlamydia/ 
gonorrhea cases (range: 3 to 100 percent).  The PPV in the meta-analysis was 9 percent—that 
is, the proportion of women incorrectly identified by the tools as having 
chlamydia/gonorrhea was 91 percent (range: 13 to 99 percent).  
 
Case finding:  female sex worker populations (high prevalence) 
An algorithm using a speculum exam and simple microscopy in a high-prevalence 
(40 percent) population of female sex workers had a sensitivity of 58 percent and PPV of 50 
percent.  Overall test efficiency reached only 60 percent. 
 
Case management among symptomatic populations 
An algorithm including a speculum exam was tested in a study in Jamaica among 
female STD clients (see Appendix Table A18) where the prevalence of chlamydia/gonorrhea 
was 32 percent (Behets et al. 1995).  Among this population, where the tool was used to 
manage cases among symptomatic women who were specifically seeking treatment for 
urogenital complaints, such an algorithm performed much better, yielding a sensitivity of 73 
percent, specificity of 56 percent, and PPV of 43 percent.  Nevertheless, more than 50 
percent of women identified by the algorithm as having chlamydia/gonorrhea were, in fact, 
not infected.  Overall test efficiency was 61 percent. 
The tool tested by Germain and colleagues among female sex workers was also 
applied to a subpopulation of the sample that was symptomatic (Germain et al. 1997).  Doing 
so increased the sensitivity (from 58 to 68 percent), but decreased the specificity (from 61 to 
39 percent), leaving the PPV the same for this symptomatic group (49 percent) as for the 
larger population of symptomatic and asymptomatic female sex workers (50 percent). 
Tools Including Risk Factors 
 
Case finding: routine clinic and general populations (moderate prevalence) 
 32
Six of the studies reviewed among routine clinic and general populations tested 15 
different tools that included combinations of questions regarding risk factors (see Appendix 
Table A19).  In meta-analysis, the PPV was 13 percent.  The algorithms or tools achieved 
PPVs ranging from 0 to 66 percent, with only one having a PPV greater than 20 percent.  
Sensitivity varied widely, ranging from 0 to 80 percent.  Although test efficiency reached 89 
percent in meta-analysis, only 22 percent of infected women were identified by the tools, and 
87 percent of women identified by the tools as having chlamydia/gonorrhea were not 
infected. 
 
Case management among symptomatic populations 
The two case-management studies among STD clinic clients tested four algorithms 
that included risk factors (see Appendix Table A19).  Sensitivity was greater than 75 percent 
for each algorithm (meta-analysis: 78 percent); specificity was 50 percent or lower.  This 
resulted, in meta-analysis, in a PPV of 40 percent, a false-positive rate of 60 percent, and a 
test efficiency of 59 percent. Although these tools identified 78 percent of women with 
chlamydia/gonorrhea, 60 percent of those identified as having chlamydia/gonorrhea were not 




Case finding: routine clinic and general populations (moderate prevalence) 
Six of the studies among routine clinic and general populations tested risk-scoring 
tools as a way to find cases of chlamydia/gonorrhea (see Appendix Table A20).  Some 
included variables obtainable only with speculum exams; others did not.  A total of 18 
different risk-scoring tools were assessed.  Meta-analysis demonstrated a test efficiency of 75 
percent.  The tools were able to identify 41 percent of those women infected (sensitivity 
range: 8 to 81 percent).  The positive predictive value was 13 percent.  All tools tested had a 
false-positive rate greater than 75 percent—that is, more than three-fourths of the women 
identified as having chlamydia/gonorrhea through these risk-scoring tools were not infected. 
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Case finding:  female sex worker populations (high prevalence) 
One of the analyses among female sex workers also tested an algorithm that included 
risk scores (see Appendix Table A20).  Within the study, the score-driven tool performed 
better than the simple hierarchical algorithm.  Among sex workers in Zaire (Vuylsteke et al. 
1993b), a score-driven strategy including variables for demographic factors, symptoms, and 
signs, and requiring a speculum exam achieved a PPV of 42 percent and sensitivity of 71 
percent.  This strategy was an improvement over the symptom-only-based algorithm that 
yielded a PPV of 34 percent and sensitivity of 55 percent (see Appendix Table A17).  Test 
efficiency of the risk score in this population of women with a high prevalence of 
chlamydia/gonorrhea was still only 61 percent (Appendix Table A20). 
 
Case management among symptomatic populations 
In the Jamaican case-management study of STD clinic clients (Behets et al. 1995), as 
in the Zairian case-finding study among sex workers (Vuylsteke et al. 1993b), the score-
driven management option performed better in terms of sensitivity than did the simple 
algorithm with a speculum exam and the algorithm that included risk factors.  The algorithm 
combined speculum exam and risk scoring of demographic and behavioral factors, including 
partners’ symptoms.  This strategy yielded a PPV of 43 percent and a sensitivity of 85 
percent. More than half (57 percent) of the women identified by the algorithm as having 
chlamydia/gonorrhea infection, however, were not actually infected.  Overall test efficiency 
was 56 percent—that is, slightly more than half of the women were correctly identified as 




Table 12, below, presents the results of the meta-analysis for the categories discussed 
above to provide a rough overview of the data from these different studies.  The various 
types of tools used to find cases of chlamydia/gonorrhea infection among general and routine 
clinic populations of women had sensitivities of 41 percent or lower and PPVs of 13 percent 
or lower.  This result means that almost 87 percent of women identified as having chlamydia/ 
gonorrhea by means of the tools, would, in fact, not be infected.  Overall test efficiency in 
these populations ranged from 73 to 89 percent because of the low prevalence of infection. 
Among female sex workers, the tools performed better for case finding on most 
measures.  Sensitivity ranged from 55 to 71 percent, and PPVs from 34 to 50 percent.  
Overall test efficiency was lower (53 to 61 percent), however, than that of the tools as used 
among general and routine clinic populations. 
The results from the studies that used the nonlaboratory tools as a way to manage 
symptomatic women—the purpose for which these tools were originally intended—are also 
better than those used for case finding among routine clinic and general populations of 
women.  Sensitivity was consistently higher (above 70 percent) for the tools tested in this 
population, although specificity was below 55 percent.  Positive predictive values ranged 
from 40 percent to 45 percent.  Thus, false-positive rates were all above 50 percent—
meaning that more than half of the women identified as having chlamydia/gonorrhea by these  





When deciding whether a particular strategy for STI control is appropriate and 
effective in a given context, different standards are employed and different measures take 
precedence.  For instance, presumptive treatment of women whose partners are known to 
have gonorrhea has only a 30 to 40 percent PPV.  In this situation, the predictive value 
implies treating ten women in order to assure that the three or four who have gonorrhea 
Table 12  Meta-analysis of nonlaboratory tools used for case finding and case management  
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a Because multiple studies are lacking, this specification represents single-study results rather than meta-analysis. 
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infection receive therapy, and most believe that this is a reasonable public health 
intervention.  However, a similar PPV for a case-finding tool to be used among family 
planning clinic populations may be considered unacceptable, because the number of women 
who would unnecessarily receive treatment would be much higher.  Decisions about whether 
the results of implementing a certain tool are reasonable and whether overtreatment would 
cause more harm than good depend on the seriousness of the infection, the number of people 
who would be overtreated, and the HIV/STI infection patterns and sexual behaviors of the 
population. 
Nonlaboratory tools used to find cases of chlamydia and gonorrhea among mixed 
symptomatic and asymptomatic patients in routine clinic and general populations generally 
appear unable to identify those women who are infected.  Sensitivity of case-finding tools in 
populations with a higher prevalence of infection appears generally to reach 50 percent or 
higher.  In all but four instances (out of 52 tools/populations tested11) however, the false-
positive rate of the tools when used for case finding was 66 percent or higher for all 
prevalence groups (that is, general and routine clinic populations and female sex workers).  
In concurrence with most authors of the studies reviewed, we conclude that these tools are 
not effective for use in chlamydia/gonorrhea infection case finding. 
The results of the case-management validation studies conducted among symptomatic 
women show that the case-management tools have what appear to be a consistently higher 
sensitivity and lower false-positive rate (higher PPVs) than when the tools are used for case 
finding.  Nevertheless, they resulted in presumptive treatment of many women with no 
infection: More than half of the symptomatic women identified as having chlamydia/ 
gonorrhea by the algorithms were not infected, and overall test efficiency ranged from 39 to 
61 percent. These statistics are disappointing and indicate that the case-management tools are 
not good diagnostics for chlamydia and gonorrhea. In contexts having a high STI prevalence, 
where HIV/AIDS is a growing concern, and where chlamydia/gonorrhea case management is 
needed for a subpopulation at high-risk (for example, STD clinic clients), the primary 
interest may be in treating the greatest number of cases (that is, high sensitivity).  In such 
situations, even a 50 percent overtreatment is seen as an acceptable consequence by some, 
                                                          
11 Some of these are the same tools tested in different populations; for example, the Zaire study tested the same algorithm 
among antenatal clinic clients and among female sex workers. 
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although others remain unpersuaded.  Nonlaboratory tools for chlamydia/gonorrhea are 
potentially much more useful as case-management tools than as case-finding tools. 
Several limitations may have affected the measures of assessment in these studies.  
On the one hand, the prevalence of chlamydia may have been underestimated.  Chlamydia 
infection may not appear in the cervix, even when it is present in the urethra.  A study in 
Somalia found that 27 percent of infected women showed chlamydia infection only from 
urethral swabs, not from cervical swabs (Ismail et al. 1990).  Because most of the studies 
reviewed used only cervical specimens to diagnose chlamydia, they may have 
underestimated the prevalence of chlamydia.  Inclusion of urethral diagnosis of chlamydia 
may affect the results of these studies, although in what direction is not clear. 
On the other hand, the usefulness of the tools for case finding was probably 
overestimated, because the results reflect evaluations of the tools used under ideal conditions.  
With the exception of the study by Behets, which looked at the usefulness of algorithms in 
managing cases under field conditions, all others simulated application of the tools.  These 
represent situations in which the algorithms, risk-scoring techniques, and so forth were 
applied under conditions where clinicians were likely to be well trained in their use—much 
better trained than clinicians not involved in such studies, who would have less 
understanding of the tool and be faced with considerably more challenging field conditions. 
A program that integrated RTI services, including case management, into clinics in the 
Philippines, for example, found that without facilitative supervision, service providers 
generally were unable or unwilling to implement the guidelines that they had learned in the 
training (Costello 1998). 
In addition, validity was probably overestimated in studies in which the tools were 
both developed and tested in the same population.  Some of the studies developed the tools 
and simulated application in the same sample that was used to identify the variables for 
inclusion in the model (for example, Kaufman et al. 1996; Braddick et al. 1990; Thongkrajai 
1996; and Costello Daly et al. 1994).  Especially for those tools that included risk factors or 
risk scoring, efficacy may be artificially high as behavioral and/or demographic risk factors 
in populations other than the original cohort may be weaker predictors of infection, may have 
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no association with infection, or may not even be correlated.  Even in the same cohort, risk 




Most researchers who have tested algorithms, risk scoring, and other nonlaboratory 
tools have concluded that these methods perform poorly for case finding of chlamydia and 
gonorrhea infections.  However, the limitations of their use among routine clinic and general 
populations have not always been apparent to managers and policymakers.   
As we can see from the results of studies conducted to date, refinements, such as the 
addition of risk scoring, produce only marginal improvement in the tools’ ability to find 
cases of chlamydia/gonorrhea among women.  The tools correctly identify too few cases and 
incorrectly identify too many women without infection as being infected, even when they are 
applied and evaluated for the same populations for which they were developed.   
There are reasons why nonlaboratory tools such as algorithms and risk scoring are 
unlikely ever to be efficient or useful for case finding.  If a disease is not common, a test 
must be both highly sensitive and specific to find most cases without also creating many false 
positives.  For example, if specificity is as high as 90 percent, then 10 percent of individuals 
without the condition will be incorrectly identified as having the condition.  If a disease is 
rare, these false positives will quickly become a larger group than the correctly identified 
infected women, a situation underscoring the desirability of confirmatory testing in low-
prevalence settings. 
Enough information exists today to conclude that these tools will not perform better 
without simple, low-cost field diagnostics. A number of STI experts have noted this need 
(Wasserheit 1989; Behets et al. 1995; Ryan and Holmes 1995; Mayaud et al. 1995; and 
Vuylsteke et al. 1993b, among others).  Although many international agencies have given 
support to the development of such diagnostics as a priority for STI research, progress has 
                                                          
12 In a selective screening program for chlamydia among family planning clinics in Wisconsin, for example, an assessment 
four years after the efforts’ initiation found that prevalence of chlamydia had decreased dramatically by approximately 53 
percent among both low-risk and high-risk groups.  As a result, the criteria identified in 1986 and used since then identified 
infected patients less efficiently in 1990, effectively doubling the cost per case identified.  Consequently, adjustments were 
made to the program based on findings from the 1990 assessment of variables correlated with infection (Addiss et al. 1993). 
 39
been slow.  Increased attention to development of simple, low-cost, valid field diagnostics—
along with adequate funding for this work—is badly needed. 
The question remains, however, what is to be done in the meantime about chlamydia 
and gonorrhea in settings where laboratory diagnosis is not available?  The consequences of 
these infections in terms of morbidity, HIV transmission, and mortality may be grave. Given 
the imperfection of current tools, more local and national decisionmaking is needed.  
Consideration of the contexts of different local settings requires not only an epidemiological 
analysis but also an understanding of programmatic capacity and social processes. No one 
clear solution exists.  “It depends,” may be the only universal response we can give to our 
self-imposed question. 
Key among the issues to consider are those related to the women who are classified 
wrongly by any clinical tool. The proportion of women affected by misdiagnosis is large.  
Among the 49 tools/populations tested for case finding in routine clinic and general 
populations, only three reached PPVs greater than 25 percent.  The vast majority did not 
reach even 20 percent, so that even given the best results, for every woman accurately treated 
for infection, four women would be treated unnecessarily and would be mislabled as 
infected.  Tools used among female sex workers had PPVs of 34, 50, and 42 percent—that is, 
more than half of the women engaged in high-risk sexual behavior would also be mislabeled 
as infected.  The proportion of women who might fall into the category of false negatives is 
also substantial.  Only 15 out of the 52 tools/populations assessed for their ability to find 
cases of chlamydia/gonorrhea among moderate- and high-prevalence populations achieved 
sensitivities greater than 60 percent.  Indeed, more than half of the tools were unable to 
detect even 50 percent of all the women with chlamydia and/or gonorrhea infection.  In 
general and routine clinic populations, tools did not reach even 50 percent sensitivity in 
meta-analysis, and tools used among sex workers achieved sensitivities of 55, 58, and 71 
percent.  We consider below the implications of using algorithms, risk scoring, and other 
tools for finding chlamydia/gonorrhea infection in those infected women who have been 
missed (false negatives) and those women who have been identified as being infected when 
they are not (false positives). 
What are the consequences for women who have been identified as uninfected but 
who may be infected?  Most obviously, they do not receive treatment for a curable 
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infection(s) and face potentially serious consequences.  In some ways, the results for the 
women who are infected but not identified as such are the same as before any service was 
provided to them.  However, because these women have been screened, they and their 
service providers may feel a false sense of security.  This feeling has consequent implications 
for advice and decisionmaking regarding STI prevention, contraceptive-method selection, 
partner communication, and prenatal and delivery care.  For instance, where IUDs are 
commonly used, women falsely identified as not infected may receive a contraceptive that is 
contraindicated for them. 
What, too, are the consequences of mislabeling women as infected with an STI when 
they are not?  First, those women will receive drugs that they do not require.  Overuse of 
antibiotics may cause resistant strains of infectious organisms to develop in the community 
that are not susceptible to treatment with available drugs.  In addition, all drugs have risks of 
side effects, including allergies and other, more serious reactions. 
In discussions about the pros and cons of nonlaboratory strategies, the question of 
what mislabeling means to the individual is rarely considered.  What are the consequences of 
telling a woman that she has a sexually transmitted infection when she does not?  They  are 
very different from what she would experience were she told that she had pneumonia or 
malaria.  First, in many contexts, social stigma is associated with having a sexually 
transmitted infection.  Second, by definition, having this sort of condition means that either 
the woman or her partner has had sexual contact with someone outside the marriage or union. 
If the woman has had such contact, does she tell her husband (since he would also need 
treatment) and acknowledge that she has had a relationship with someone else?  If she has 
not, does she, making the assumption that the infection could only come from her husband, 
confront him and accuse him of infidelity?  Does she say nothing, but insist on condom use 
in the future?  Is insisting on condom use something that is possible for her, given the power 
differentials in the relationship?  What does a misdiagnosis do in terms of undermining a 
woman’s trust in her partner and their relationship, or of his trust in her? 
The optimum contents of the messages that should accompany the results derived 
from using these tools have not been fully explored. Because the tools are imperfect, the 
message to be relayed is complex; the woman may be told that she may have some kind of an 
infection that may or may not be sexually transmitted. In a larger sense, the issue of client–
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provider communication about sensitive topics has been woefully neglected by the 
reproductive health and population field.  Thus, many service providers, aware of the 
complexities of STI counseling, are confused about how to handle such situations.  For 
example, the clinicians working on an STI study in Hue, Vietnam, found that although they 
had treated many women for presumed infections in the past, that study for the first time 
made a confirmed laboratory diagnosis of trichomoniasis possible.  With a confirmed STI 
diagnosis, clinicians had to face the difficult challenge of specific counseling and partner 
notification (Phan Thi Lien et al. 1998). 
How do we counsel women that they might have an STI but probably have an 
endogenous infection?  How do we tell a woman that if she does have an STI, her partner/s 
may have one as well?  When the provider does not know whether a woman has an STI, the 
appropriate counseling may be to tell her she is being treated for a range of infections, some 
of which are sexually transmitted, but many of which are not.  The complexity of this 
counseling message is an operational issue that has largely gone unevaluated.  Information 
that is available indicates that providers often do not tell a woman that she has an STI unless 
they are absolutely sure and, even if they are sure, the provider may not inform the woman 
because the topic is difficult or uncomfortable to discuss (Iskandar et al. 1997). In some 
instances, providers choose not to communicate this possibility, either because they are not 
comfortable with issues involving sexual behavior or because they deliberately seek to avoid 
the social implications for the couple.  However, withholding full information about the 
medical condition of a patient and treatment choices may be ethically unacceptable. 
Partner nofitication is equally complicated.  Discussing an actual or suspected 
sexually transmitted infection with a partner is not easy in the best of circumstances, and in 
the worst, can be physically harmful to the woman, or can lead to divorce or dissolution of a 
relationship.  A husband whose wife tells him that he must be treated for an infection, or that 
she would like to use a condom always has the option of denial and of accusing her of having 
an extramarital liaison.  In contexts where women’s sexuality is strictly controlled, a woman 
who tells her husband that she has an STI may be at great risk.  Clearly, women are better off 
knowing about a real infection, but the counseling, course of action, and partner notification 
issues are complex and are underexamined. 
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Partner-notification strategies in the reproductive health and family planning field are 
still being explored.  In many settings, practitioners are ill-equipped to conduct such 
programs in a manner that is supportive of women.  The implications of this weakness are 
troubling in those situations where we can confirm infection with laboratory diagnosis.  
However, where clinicians are relying on nonlaboratory management tools, an even greater 
need exists for consideration of the implications.  What does “partner notification” mean in 
the context of syndromic management? 
VI. Conclusion 
 
We are thus left with a thorny situation.  The consensus is that reproductive tract 
infections constitute a widespread public health problem requiring attention.  The problem is 
made particularly acute by sexually transmitted infections’ contribution to HIV transmission 
and the urgency of slowing the HIV/AIDS pandemic.  Many governments, donors, and 
nongovernmental organizations feel the necessity of doing something now to address RTIs in 
service delivery.  Some propose that basing services in low-resource settings on 
nonlaboratory tools such as algorithms and risk scores to find and treat cases, if not a perfect 
strategy, must be better than doing nothing.  Others contend that doing so may, in fact, be 
worse than doing nothing.  As is shown here, research to date suggests that these tools are 
severely limited. 
On the one hand, imperfect tools exist that perform poorly when used to find cases in 
populations with a moderate prevalence of these infections and perform better at managing 
cases among symptomatic women (but that still presumptively treat a large proportion of 
women who are not infected).  On the other hand, a broad range of regional, national, and 
local settings must be considered that have vastly different contextual variables regarding 
sexually transmitted infections, HIV/AIDS prevalence, sexual behavior patterns, health-
seeking behavior, and programmatic capacity.  Clearly, there is no single solution.  Case 
management of chlamydia/gonorrhea might be a smart policy decision in an STD clinic in a 
community with high prevalence, but may generate too few identified cases and too much 
overtreatment in maternal and child health or family planning clinics in any circumstances. 
An acute need exists for informed policy choices that take local contexts into account. 
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Essentially, two tasks must be faced:  (1) to manage simply, safely, and cheaply the 
common problem of symptomatic vaginal infection;  and (2) to detect and treat cervical 
infection in those regions and among those populations for whom the prevalence is high 
enough to justify the effort.  What we see from this review is that accomplishment of the first 
task is not a path to resolution of the second. 
The following challenges are evident for policymakers, researchers, and program 
managers.  We view these items as starting points for further discussion and exploration. 
(1) Depending on the prevalence of chlamydia and gonorrhea, different responses will be 
appropriate.  In some settings, where the prevalence of chlamydia/gonorrhea is too 
low to be viewed as a public health concern, it is probably best to abandon attempts 
to find cases of cervical infection among women who are not presenting for treatment 
of symptoms. In such settings, trying to distinguish chlamydia/gonorrhea among 
symptomatic women by using algorithms, risk scores, and other nonlaboratory tools 
may also not be worthwhile. 
Where the prevalence of chlamydia/gonorrhea is very high, more radical measures such 
as periodic presumptive treatment form part of the options that policymakers should 
consider.  For instance, in Rakai, Uganda, a randomized trial of intensive STI control 
via presumptive treatment for women during pregnancy achieved declines in the 
prevalence of chlamydia and gonorrhea (as well as in that of trichomoniasis and 
bacterial vaginosis) in the intervention area (Gray et al. 1998). 
In settings having a medium prevalence of these infections, a mixture of targeted 
strategies such as contact tracing and selective laboratory screening may be the 
appropriate response.  What levels of prevalence and what contextual variables 
should trigger the adoption of one option over another is a topic for further research 
and policy analysis. 
(2) A central question is whether using nonlaboratory case-finding or case-management 
tools is a better approach than simply following current routine practice for 
identifying and treating chlamydia and gonorrhea in reproductive health service 
settings.  From the results of the studies reviewed in this paper, the tools are clearly 
shown to be ineffective for finding cases of chlamydia/gonorrhea.  In terms of case 
management, many community-based clinics already rely on some ad hoc 
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management of symptomatic patients—either referring them to a higher level of care 
or prescribing available antibiotics.  Others do not.  Does using algorithms, risk 
scores, and other nonlaboratory tools add value to current practice?  Or does it do 
more harm than good?  Findings from the Hue study indicate that in central Vietnam, 
although use of flowcharts for managing symptomatic women significantly reduced 
overtreatment of vaginal infections, the flowchart performed as poorly as did current 
clinical practice for cervical infection (chlamydia and gonorrhea) (Phan Thi Lien et 
al. 1998). 
(3) The potential for improving training and supervision can be one reason to standardize 
case management.  Where effective case-management tools are adopted, the strategy 
can provide standard guidelines and procedures that support clinicians better in 
helping symptomatic women and provide more consistent data for monitoring.  
Training in such systems may also provide a vehicle for broadening the providers’ 
views of their own roles beyond the reflexive prescription of antibiotics.  Clearly, no 
one case-management tool can serve this purpose across settings.  The content of the 
case-management guidelines must be specific to the local and national context. 
(4) In all program applications of nonlaboratory approaches, training and supervision 
should be focused on supporting providers in discussing intimate topics, including 
sexual behavior.  The probability that an STI management decision or diagnosis is 
correct must also be broached.  Providers must be able to provide support in assisting 
a woman to make her own decisions regarding treatment and prevention of infection, 
and contraceptive choice, and to offer assistance and support, if the woman wants it, 
in notifying and counseling her partner(s).  Without a process of information 
exchange regarding these issues—particularly the health implications of a woman’s 
and her partner’s sexual behavior—the usefulness of any STI management strategy is 
undermined. Although experiments in incorporating providers’ attention to sexuality 
into discourse with clients have been tried successfully in a few settings (Becker and 
Leitman 1997), the vast majority of reproductive health settings lack this capacity.  
The question of how best to support providers in discussing intimate topics and 
changing the nature and content of their conversations with clients needs further 
research. 
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(5) Because of the disappointing results of the algorithms, risk scores, and other tools for 
finding chlamydia and gonorrhea among women, case finding could, with tools 
currently available, be centered on finding symptomatic men, improving counseling 
for men and partner notification, and improving counseling and treatment among 
their female partners. 
(6) Alternative service-delivery options that could be explored include the following: 
a) Because gonorrhea appears to show consistently lower prevalence than 
chlamydia, the effects could be tested of dropping the gonorrhea treatment from 
the empiric treatment recommendations as a means of lowering the cost and 
danger of overtreatment when managing clients presenting with symptoms. 
b) A “two-visit” algorithm could be tested according to which symptomatic women 
first receive treatment for vaginitis and then revisit for persistent symptoms.  This 
strategy may not be feasible in all settings, but should be evaluated in the private 
sector where, at least in parts of Asia and Latin America, most care is received 
and revisits are the norm.  
c) In some settings, these management strategies might be of greater benefit when 
used in conjunction with laboratory capacity, or eventually with low-cost field 
diagnostic tests in a broader range of settings. 
(7) All research assessing the usefulness of management tools based on signs, symptoms, 
and social and behavioral risk factors should include a scientifically adequate 
validation component to ensure that research benefits directly the populations among 
whom the work is conducted.  At the same time, such validation will add to the core 
of scientific information enabling more informed discussion of this difficult matter. 
Research on other related aspects of case management, such as developing 
appropriate counseling messages, may not require definitive diagnosis of infection 
per se, but should follow ethical guidelines that ensure women’s confidentiality and 
safety. 
(8) Finally, simple, accurate, rapid, low-cost diagnostics are desperately needed. Finding 
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Screening Criteria for Signs, Symptoms, Simple Tests, and Risk Factors Used for 
Identifying Case Status of Gonorrhea and Chlamydia, and Nonlaboratory Tools Used 
to Identify Case Status 
 
 
Tables A1-A16 Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 































































































Mayaud et al. 1995 Tanzania, 
rural 














































































planning, and antenatal 
clinic populations 






































Female sex workers 











a Chlamydia only.  b Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of gonococcal cervicitis (GC) only included 
in meta-analysis to produce highest screening utility. 
 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 










































































































Vuylsteke et al. 
1993b 











































Table A2b   Symptom: Malodorous vaginal discharge, by study, according to selected measures 
































Kaufman et al. 
1996b,c 















Ronsmans at al. 
1996a 
















































a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility.  c Gonorrhea only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 






































































































Kaufman et al. 
1996b,c 

















































Table A2d   Symptom: Clumped, thick, or frothy vaginal discharge, by study, according to selected measures 













Kaufman et al. 
1996a 













Kaufman et al. 
1996b,c 













































a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility.  c  Gonorrhea only.  d  Screening criteria numerators and denominators estimated from marginal data, may reflect small (n = 1 or 2) errors, but would 




Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 
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1996 
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Mayaud et al. 1995 Tanzania, 
rural 













Ronsmans et al. 
1996a 





































Vuylsteke et al. 
1993b 





























Vuylsteke et al. 
1993b 



























a  Chlamydia only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 
























































Bourgeois et al. 
1996 


























Herrmann et al. 
1996a 
















Kaufman et al. 
1996a 













Kaufman et al. 
1996b,c 













Mayaud et al. 1995 Tanzania, 
rural 













Ronsmans et al. 
1996a 













Ronsmans et al. 
1996a,b 


























Vuylsteke et al. 
1993b 










































Vuylsteke et al. 
1993b 



























a Chlamydia only.  b Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 





Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 




















































































Herrmann et al. 
1996a 















Ronsmans et al. 
1996a 


























Vuylsteke et al. 
1993b 





























Vuylsteke et al. 
1993b 














































Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 







































































Bourgeois et al. 
1996 


























Kaufman et al. 
1996a 













Kaufman et al. 
1996b,c 













Ronsmans et al. 
1996a 


























Vuylsteke et al. 
1993b 





























Vuylsteke et al. 
1993b 



























a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 






Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 
























































Herrmann et al. 
1996a 















Ronsmans et al. 
1996a 



























Vuylsteke et al. 
1993b 





























Vuylsteke et al. 
1993b 













a  Chlamydia only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 




















































































Vuylsteke et al. 
1993bb 














































PMNs = Polymorphonuclear leukocytes. 
a  Chlamydia only.  b  Not included in meta-analysis so as to include single-study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility. 
 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 




























































































































































































































planning, and antenatal 
clinic populations 











Germain et al. 1997 Benin >10 PMN/field 
urine 













Germain et al. 1997b Benin >10 PMN/field 
cervical discharge 














Female sex workers  











HPF = High power field. PMN = Polymorphonuclear leukocyte. 
a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest s screening utility.  c  Gonorrhea only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 







































































Costello Daly et al. 
1994c 











Herrmann et al. 1996a Nicaragu
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Mayaud et al. 1995 Tanzania
, rural 











Thomas et al. 1994 Kenya <25 
 






















Ronsmans et al. 
1996a 











Vuylsteke et al. 
1993b 









































Mathews 1998  
South 
Africa 
< 25 27.3 With sexually 

























Vuylsteke et al. 
1993b 












Female sex workers  











a  Chlamydia only.   b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 




Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 

































































































Costello Daly et al. 
1994b 
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Vuylsteke et al. 
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a  Chlamydia only.  b  Gonorrhea only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 
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1996a 
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Mayaud et al. 1995 Tanzania, 
rural 


























Thongkrajai 1997 Thailand, 
rural 




























planning, and antenatal 
clinic populations 

























Female sex workers  















Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 














































































































planning, and antenatal 
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a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis 
 to produce highest screening utility.  c  Gonorrhea only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 
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1996a 


























Vuylsteke et al. 
1993b 





























Vuylsteke et al. 
1993b 

















Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 







































































Costello Daly et al. 
1994b 













Herrmann et al. 
1996a 















Ronsmans et al. 
1996a 





























a  Chlamydia only.  b  Gonorrhea only. 
 
Screening criteria for signs, symptoms, simple tests, and risk factors to identify case status for chlamydia and/or gonorrhea 









































































Costello Daly et al. 
1994b 













Herrmann et al. 
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Kaufman et al. 1996 China, 
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Ronsmans et al. 
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Tables A17–A20 Nonlaboratory tools used to identify case status 

























































Case finding  
Routine clinic and general populations  
Kapiga et al. 
1996 


















(Reported vaginal discharge 



















(Reported vaginal discharge, 
genital itching, lower 
































Vuylsteke et al. 
1993b 
Zaire 1st level, hierarchical 
(Algorithm for vaginal 
discharge and lower 
abdominal pain in settings 































Female sex workers  
Vuylsteke et al. 
1993b 
Zaire 1st level, hierarchical 
(Algorithm for vaginal 
discharge and lower 
abdominal pain in settings 
where speculum exam is not 
possible) 













a  Chlamydia only.  b  Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility. 
 
Table A18   Simple management tools using speculum exams for case finding in routine clinic and general populations and among female sex  
























































Case finding  





















































al. 1996 a,b 
Mexico, 
rural 













Costello Daly et al. 
1994c 






























All 3 major signs  
(Yellow, green, or bloody 
discharge, thick discharge, and 



































S1 + exam 
(If reported symptoms [S1], then 
examined, and treated only if 















Ronsmans et al. 
1996a 















Vuylsteke et al. 
1993b 
Zaire Other hierarchical (algorithm for 
vaginal discharge and lower 
abdominal pain in settings where 



























































































Female sex workers  
Germain et al. 
1997 
Benin Algorithm (Speculum exam and 
vaginal wet mount, mucopus, 
yellow  swab,  vaginal leucocytes 
>10/field) 




























Case management  
Behets et al. 1995 Jamaica Algorithm A  
(Examine cervix; if detect cervical 

















Germain et al. 
1997 
Benin Algorithm (Speculum exam and 
vaginal wet mount, mucopus, 
yellow  swab,  vaginal leucocytes 
>10/field but used among 
symptomatic females only 
[vaginitis]) 


























GUSS = genitourinary signs and symptoms: urinary symptoms, cervical inflammation, friability, and mucopurulent discharge. 
a  Chlamydia only.  b  Not included in meta-analysis so as  to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility.  c  Gonorrhea only. 
 
 
Table A19   Management strategies that include risk factors, for case finding in routine clinic and general populations, and for case management among  























































Case finding  
Routine clinics and general populations  
Bourgeois et al. 
1996 
Gabon Algorithm: Reported symptoms 
+ clinical exam + speculum;  














Bourgeois et al. 
1996b 
Gabon Algorithm:  Age <25, marital 
status, reported symptoms + 















Bourgeois et al. 
1996b 
Gabon Algorithm:  Reported vaginal 
discharge, and at least 2 of:  
age <25; marital status; lower 















Braddick et al. 
1990 
Kenya Clinical cervicitis and/or >1 















Braddick et al. 
1990b 
Kenya Clinical cervicitis and >1 partner 














Costello Daly et al. 
1994 b,c 













Costello Daly et al. 
1994b,c 













Costello Daly et al. 
1994b,c 
Kenya Unmarried and/or >1 partner in 















Costello Daly et al. 
1994c 
Kenya Unmarried and >1 partner in 




























Meda et al. 1997 Burkina 
Faso 
Length of relationship w/ regular 
partner <3 years, and urine 

















Ronsmans et al. 
1996a 
Turkey Reported discharge in husband 















































































































General, family planning, and 
antenatal clinic populations 











Case management  
Behets et al. 1995 Jamaica Adjusted Algorithm A: 
Examine cervix; if detect cervical 
mucopus, treat for chlamydia/ 
gonorrhea (but only applied to 
women who have not been referred 
by a symptomatic partner) 














Coetzee and Mathews 1998 South 
Africa 


















Coetzee and Mathews 1998b South 
Africa 
Standard algorithm: 
Women, < 45 years of age, 
sexually active, not pregnant, and 
pre-menopausal, reporting vaginal 


















Coetzee and Mathews 1998b South 
Africa 





























PMN = Polymorphonuclear leukocytes   
a Chlamydia only.  b Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility.  c Gonorrhea only.  d Women who complain of abdominal pain are diagnosed with cervicitis if they have a temperature >38º C or pain on cervical 
motion.  Women who complain of vaginal discharge are diagnosed with cervicitis and vaginitis if they are at high risk of STDs (that is, partner is symptomatic or at least two of: age <21; 
single; >1 partner; new partner in last three months).  When the risk assessment is negative, these women are diagnosed with vaginitis.  e In settings where a vaginal exam is not 
possible, women are diagnosed with cervicitis (due to chlamydia/gonorrhea) if they complain of vaginal discharge and are at high risk of STDs (that is, partner symptomatic, or any two 
of: age<21 years; single; >1 partner; new partner in last three months). f In settings where a clinical exam is possible (including vaginal and abdominal exam), women are diagnosed with 
cervicitis (due to chlamydia/gonorrhea) if they complain of vaginal discharge and are at high risk of STDs (see note above) or if they complain of vaginal discharge and a speculum exam 
reveals mucopurulent discharge from the cervix.  Women in this setting who complain of lower abdominal pain are diagnosed with pelvic inflammatory disease (PID) (due to 
chlamydia/gonorrhea) if they have a temperature >38ºC, pain on cervical motion, or vaginal discharge.
 
Table A20   Management strategies including risk scoring for case finding in routine clinic and general populations and among female sex workers and  
























































Case finding  
Routine clinics and general populations  
Bourgeois et 
al. 1996 
Gabon Algorithm 1 (score >3): age <25, 
vaginal discharge symptom, low 
back pain, yellow-green  discharge 
clinical exam, malodorous 
discharge clinical exam; any 1 of 3: 

















Gabon Algorithm 2 (score >3): = Algorithm 

















Gabon Algorithm 3 (score >3): = Algorithm 
2 w/o malodorous discharge + 
















Gabon Algorithm 4 (score >3): = Algorithm 
1 w/o malodorous discharge, + 














Kapiga et al. 
1996 
Tanzania Score ≥ 1, examine and treat if 














Kapiga et al. 
1996b 
Tanzania Score >1 
Variables: New partner in last 3 
months (2); >1 partner (1); 
cohabiting (1); single (2); <20 yrs 
(1); husband <25 yrs (2); 
symptoms of vaginal discharge (2); 
dysuria (2). Score = sum of points 














Kapiga et al. 
1996b 















Kapiga et al. 
1996b 
Tanzania Score 1–3; examine and treat if 




















Women with a risk score (R1 
simplified) > the cutoff value are 
treated only if abnormal vaginal 













































































(R1- Score based on sociodemo-
graphic factors ≥  the cutoff value.  
Optimal score obtained from logistic 
regression coefficients [x10] of 




















(R1- Same as above. Simplified, 



















(R2- Score based on sociodemo-
graphic factors and reported 
symptoms ≥ the cutoff value. 






































Women reporting symptoms (S1) are 
questioned and treated only if their 















Thomas et al. 
1994 
Kenya Tanzania  
R1 Simplified  
















Thomas et al. 
1994b 
Kenya Zaire risk score 



















Thailand Score driven 
Variables: Husbands’ frequency of 
working away from home; husband 
and wife living together during last 
three months and lower abdominal 
pain.  Scores of 11,10, and 8 
assigned, respectively. Scores 
summed, value >8 = decision to 
treat. 




































































Vuylsteke et al. 
1993b 
Zaire Score driven 
Variables: single (5); >1 partner in last 
year (10); <25 years (14); 25–34 years 
(11); reported vaginal discharge (1); 
lower abdominal pain (3); LED (10, 12, 































Female sex workers 
Vuylsteke et al. 
1993b 
Zaire Score driven  
Variables: single (5); >1 partner in last 
year (10); <25 years (14); 25–34 years 
(11); reported vaginal discharge (1); 
lower abdominal pain (3); LED (10, 12, 
15). Total score of >28 considered 
infected. 




























Behets et al. 
1995 
Jamaica Algorithm B 
Risk-assessment variables: partner 
has urethral discharge (2); <21 years 
(1); new partner in last 3 months (1); 
>1 partner in last 3 months (1); not 
living with steady partner (1). If score 
is >2, treat for chlamydia/gonorrhea. If 
score <2, examine with speculum for 
















LED = Leukocyte esterase dipstick. 
a Chlamydia only.  b Not included in meta-analysis so as to include single study only once. Specification with best test efficiency or CT instead of GC only included in meta-analysis to 
produce highest screening utility. 
 
